<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00746720</url>
  </required_header>
  <id_info>
    <org_study_id>02B2005</org_study_id>
    <secondary_id>EudraCT No.: 2005-003854-80</secondary_id>
    <nct_id>NCT00746720</nct_id>
  </id_info>
  <brief_title>Modulation of the Surgical Inflammatory Response by Etoricoxib</brief_title>
  <official_title>Modulation of the Surgical Inflammatory Response by Etoricoxib: Peripheral Versus Central</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Erlangen-Nürnberg Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>HELIOS Kliniken GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rush University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Erlangen-Nürnberg Medical School</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the hypothesis that orally administered etoricoxib
      (COX-2) modulates prostaglandin and cytokine synthesis in the central nervous system (CNS)
      and in the periphery in surgical patients and thus reduces pain and suffering.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be a multiple centre, double-blind, placebo-controlled, randomized, parallel
      group study conducted in male and female adult patients undergoing elective primary single
      hip arthroplasty. In part 1 of the study 12 patients will be enrolled in the study and will
      be administrated 120 mg Etoricoxib or placebo orally on day one post surgery. The results
      from part 1 should help to adjust sampling time points (for blood, cerebrospinal fluid and
      hip drain fluid) if necessary. In part 2 of the study 40 patients will be enrolled and should
      receive 120 mg etoricoxib or placebo two hours before and 24 hours after surgery.

      Primary end points will be the inflammatory mediators on peripheral and central levels. After
      surgical manipulation we expect increased mediators on both sides. It will be investigated if
      the medication could reduce the mediators compared to placebo and if the effect is related to
      pharmacokinetic parameters.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Patient recruitment difficulties
  </why_stopped>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To test the hypothesis that orally administered etoricoxib (COX-2 inhibitor) modulates prostaglandin and cytokine synthesis in the central nervous system (CNS) and in the periphery in surgical patients.</measure>
    <time_frame>within 24 hours post dosing (study part 1) and within 48 hour post dosing (study part 2)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the CSF (cerebrospinal fluid), plasma and tissue pharmacokinetics of orally administered etoricoxib.</measure>
    <time_frame>within 24 hours post dosing (study part 1) and within 48 hours post dosing (study part 2)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To correlate the prostaglandin and cytokine response to clinical outcome parameters after hip arthroplasty.</measure>
    <time_frame>within 4 days post dosing (study part 1 and 2)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the safety (via clinical laboratory tests and adverse events) of a single dose of 120 mg Etoricoxib for one day (Part1) or for two days (Part2) and placebo.</measure>
    <time_frame>within 4 days post dosing (study part 1 and 2)</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Pain</condition>
  <condition>Osteoarthritis, Hip</condition>
  <condition>Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>A, 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study part 1 (n = 8)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A, 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Study part 1 (n = 4)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B, 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study part 2 (n = 20)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B, 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Study part 2 (n = 20)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoricoxib 60 mg</intervention_name>
    <description>film coated tablet 60 mg (orally), 120 mg (= 2 tablets a 60 mg) once daily, on day one post surgery</description>
    <arm_group_label>A, 1</arm_group_label>
    <other_name>Arcoxia 60 mg</other_name>
    <other_name>MK0663</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for Etoricoxib 60 mg</intervention_name>
    <description>film coated tablet (orally), two tablets once daily, on day one post surgery</description>
    <arm_group_label>A, 2</arm_group_label>
    <other_name>Matching Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoricoxib 60 mg</intervention_name>
    <description>film coated tablet (orally), 120 mg (= 2 tablets a 60 mg) once daily, two hours before and 24 hours after surgery</description>
    <arm_group_label>B, 1</arm_group_label>
    <other_name>Arcoxia 60 mg</other_name>
    <other_name>MK0663</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for Etoricoxib 60 mg</intervention_name>
    <description>film coated tablet (orally), 2 tablets once daily, two hours before and 24 hours after surgery</description>
    <arm_group_label>B, 2</arm_group_label>
    <other_name>Matching Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject undergoing elective primary single hip arthroplasty

          -  Subject diagnosed with Osteoarthritis / arthrosis

          -  Subject has not taken non-steroidal anti-inflammatory drugs within 4 of their terminal
             half life times prior to enrollment

          -  Subject capable of understanding and cooperating with the requirements of the study

        Exclusion Criteria:

          -  Patients with renal insufficiency (serum creatinine &gt;1.5 mg/dl)

          -  Recent major trauma or systemic infection (within 3 months)

          -  Use of corticosteroid medication or chronic opioids (within 3 months)

          -  Any other condition likely to affect prostaglandin and cytokine levels

          -  Participation in another clinical study or receipt of an investigational drug within
             30 days

          -  Hypersensitivity to any component of the etoricoxib and/or placebo tablets

          -  Uncontrolled hypertension defined as systolic blood pressure &gt;140 mm Hg and diastolic
             pressure &gt;90 mm Hg at rest after two repeated measurements

          -  Congestive heart failure (NYHA II-IV)

          -  Cerebrovascular disease

          -  Established ischemic heart disease (including patients who have recently undergone
             coronary artery bypass graft surgery or angioplasty)

          -  Patients with any kind or severity of cirrhosis of the liver or cholestasis or
             elevated liver function enzymes (ALT or AST 3 fold) as a sign of clinical significant
             liver malfunction (corresponds to any Child-Pugh-Score ≥5)

          -  Patients who have developed signs of asthma, acute rhinitis, nasal polyps,
             angioneurotic oedema or urticaria following the administration of aspirin or other
             non-steroidal anti-inflammatory drugs (NSAIDs)

          -  Pregnancy and lactation

          -  Patients with active peptic ulcerations or active gastro-intestinal (GI) bleeding

          -  Inflammatory bowel disease

          -  Recent history (within the last year) of alcohol or other substance abuse

          -  An employee of the sponsor or study site

          -  Any neurological syndrome or any other condition leading to contra-indication to
             spinal anesthesia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kay Brune, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of Erlangen-Nürnberg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Josef Zacher, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helios Klinikum Berlin</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martin Fromm, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Erlangen-Nürnberg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Asokumar Buvanendran, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rush University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>HELIOS Klinikum Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>D-13125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Buvanendran A, Kroin JS, Berger RA, Hallab NJ, Saha C, Negrescu C, Moric M, Caicedo MS, Tuman KJ. Upregulation of prostaglandin E2 and interleukins in the central nervous system and peripheral tissue during and after surgery in humans. Anesthesiology. 2006 Mar;104(3):403-10. Erratum in: Anesthesiology. 2006 Apr;104(4):900.</citation>
    <PMID>16508385</PMID>
  </reference>
  <results_reference>
    <citation>Renner B, Zacher J, Buvanendran A, Walter G, Strauss J, Brune K. Absorption and distribution of etoricoxib in plasma, CSF, and wound tissue in patients following hip surgery--a pilot study. Naunyn Schmiedebergs Arch Pharmacol. 2010 Feb;381(2):127-36. doi: 10.1007/s00210-009-0482-0. Epub 2010 Jan 6.</citation>
    <PMID>20052461</PMID>
  </results_reference>
  <results_reference>
    <citation>Renner B, Walter G, Strauss J, Fromm MF, Zacher J, Brune K. Preoperative administration of etoricoxib in patients undergoing hip replacement causes inhibition of inflammatory mediators and pain relief. Eur J Pain. 2012 Jul;16(6):838-48. doi: 10.1002/j.1532-2149.2011.00062.x. Epub 2011 Dec 19.</citation>
    <PMID>22337568</PMID>
  </results_reference>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 3, 2008</study_first_submitted>
  <study_first_submitted_qc>September 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 4, 2008</study_first_posted>
  <last_update_submitted>May 2, 2012</last_update_submitted>
  <last_update_submitted_qc>May 2, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 3, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hip replacement</keyword>
  <keyword>osteoarthritis</keyword>
  <keyword>etoricoxib</keyword>
  <keyword>pain</keyword>
  <keyword>cerebrospinal fluid</keyword>
  <keyword>pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Pain, Postoperative</mesh_term>
    <mesh_term>Osteoarthritis, Hip</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoricoxib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

